SG10201913359TA - Combination therapies for melanoma comprising administering cobimetinib and vemurafinib - Google Patents

Combination therapies for melanoma comprising administering cobimetinib and vemurafinib

Info

Publication number
SG10201913359TA
SG10201913359TA SG10201913359TA SG10201913359TA SG10201913359TA SG 10201913359T A SG10201913359T A SG 10201913359TA SG 10201913359T A SG10201913359T A SG 10201913359TA SG 10201913359T A SG10201913359T A SG 10201913359TA SG 10201913359T A SG10201913359T A SG 10201913359TA
Authority
SG
Singapore
Prior art keywords
vemurafinib
melanoma
combination therapies
cobimetinib
administering
Prior art date
Application number
SG10201913359TA
Inventor
Gordon Bray
Iris Chan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49035547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201913359T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG10201913359TA publication Critical patent/SG10201913359TA/en

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0241—Advertisements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Business, Economics & Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Strategic Management (AREA)
  • Development Economics (AREA)
  • Accounting & Taxation (AREA)
  • Finance (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Economics (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • Game Theory and Decision Science (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Marketing (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
SG10201913359TA 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib SG10201913359TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261684673P 2012-08-17 2012-08-17
US201261705575P 2012-09-25 2012-09-25
US201261706026P 2012-09-26 2012-09-26
US201261722725P 2012-11-05 2012-11-05
US201361780708P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
SG10201913359TA true SG10201913359TA (en) 2020-02-27

Family

ID=49035547

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201500582UA SG11201500582UA (en) 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
SG10201913359TA SG10201913359TA (en) 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
SG10201708494QA SG10201708494QA (en) 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201500582UA SG11201500582UA (en) 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201708494QA SG10201708494QA (en) 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib

Country Status (31)

Country Link
US (3) US11087354B2 (en)
EP (1) EP2884979B1 (en)
JP (2) JP6335169B2 (en)
KR (5) KR20220165811A (en)
CN (2) CN104640545A (en)
AU (1) AU2013304021B2 (en)
BR (1) BR112015003418A2 (en)
CA (2) CA2879252C (en)
CL (1) CL2015000345A1 (en)
CO (1) CO7180225A2 (en)
DK (1) DK2884979T3 (en)
EA (1) EA033573B1 (en)
ES (1) ES2743427T3 (en)
HK (1) HK1206605A1 (en)
HR (1) HRP20191533T1 (en)
HU (1) HUE044789T2 (en)
IL (1) IL237065B (en)
LT (1) LT2884979T (en)
MX (1) MX367970B (en)
MY (1) MY180613A (en)
NZ (1) NZ744862A (en)
PE (1) PE20151156A1 (en)
PH (1) PH12015500186A1 (en)
PL (1) PL2884979T3 (en)
PT (1) PT2884979T (en)
RS (1) RS59113B1 (en)
SG (3) SG11201500582UA (en)
SI (1) SI2884979T1 (en)
UA (1) UA114923C2 (en)
WO (1) WO2014027056A1 (en)
ZA (1) ZA201500348B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220165811A (en) * 2012-08-17 2022-12-15 에프. 호프만-라 로슈 아게 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
US20230190750A1 (en) * 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CZ2015250A3 (en) * 2015-04-14 2016-10-26 Zentiva, K.S. Vemurafenib amorphous forms
EP3297630A1 (en) * 2015-05-22 2018-03-28 Plexxikon Inc. Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
TWI795344B (en) 2015-06-30 2023-03-11 美商建南德克公司 Immediate-release tablets containing a drug and processes for forming the tablets
US10959993B2 (en) 2015-11-03 2021-03-30 Genentech, Inc. Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer
MX2018006152A (en) * 2015-11-19 2018-09-17 Genentech Inc Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors.
WO2017095826A1 (en) * 2015-11-30 2017-06-08 The Regents Of The University Of California Combination therapy for treatment of melanoma
CA3032542A1 (en) 2016-08-12 2018-02-15 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
CA3038671A1 (en) 2016-09-29 2018-04-05 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN116531511A (en) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Adjuvant therapy of HER2 positive breast cancer
US11395823B2 (en) 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
CN109879855B (en) * 2019-03-26 2021-01-05 中国医学科学院医药生物技术研究所 Inhibitor targeting PD-L1 molecule on surface of tumor cell and application thereof
WO2021229439A1 (en) * 2020-05-12 2021-11-18 Novartis Ag Therapeutic combinations comprising a craf inhibitor
KR20230156731A (en) 2021-03-09 2023-11-14 제넨테크, 인크. Belvarafenib for use in the treatment of brain cancer
EP4319749A1 (en) 2021-04-06 2024-02-14 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526008A (en) 2001-12-04 2005-09-02 オニックス ファーマシューティカルズ，インコーポレイティド RAF-MEK-ERK pathway inhibitors for treating cancer
AU2003218157C1 (en) 2002-03-13 2011-11-24 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2003286447A1 (en) 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
ES2369835T3 (en) 2003-11-19 2011-12-07 Array Biopharma, Inc. BICYCLIC MEK INHIBITORS AND SYNTHESIS METHODS OF THE SAME.
DK1696920T3 (en) 2003-12-19 2015-01-19 Plexxikon Inc RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
PL1913157T5 (en) 2005-06-28 2017-09-29 Genentech Inc Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
WO2007013997A2 (en) 2005-07-22 2007-02-01 H. Lee Moffitt Cancer Center And Research Institute Inhibition of the raf/mek/p-erk pathway for treating cancer
CA3052368A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors
EA017799B1 (en) * 2006-09-13 2013-03-29 Такеда Фармасьютикал Компани Лимитед Use of 2-[6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluorobenzonitrile
KR20090071603A (en) 2006-09-19 2009-07-01 노파르티스 아게 Biomarkers of target modulation, efficacy, diagnosis, and/or prognosis for raf inhibitors
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
EP2118322A2 (en) 2007-03-13 2009-11-18 Amgen Inc. K-ras and b-raf mutations and anti-egfr antibody therapy
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
UA99731C2 (en) 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Crystalline polymorphic forms of n-(2-arylamino) aryl sulfonamides as inhibitors of mek, a composition (variants) and use
US20110003809A1 (en) 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
US8338452B2 (en) 2008-02-29 2012-12-25 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2716949A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
PE20091623A1 (en) 2008-02-29 2009-11-19 Array Biopharma Inc 1H-PYRAZOLO [3,4-b] PYRIDINE DERIVATIVES AS RAF KINASE INHIBITORS
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
DE102008059206A1 (en) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic
NZ594398A (en) * 2009-04-03 2014-03-28 Plexxikon Inc Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof
AU2010289794B2 (en) 2009-08-24 2014-10-02 Genentech, Inc. Determining sensitivity of cells to B-Raf inhibitor treatment by detecting Kras mutation and RTK expression levels
JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2010314287A1 (en) * 2009-10-12 2012-05-03 F. Hoffmann-La Roche Ag Combinations of a PI3K inhibitor and a MEK inhibitor
EP2488184A4 (en) 2009-10-12 2013-04-24 Glaxosmithkline Llc Combination
WO2011104694A2 (en) * 2010-02-26 2011-09-01 GAMMAGENETICS Sàrl Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes
MX343368B (en) 2010-03-09 2016-11-01 The Broad Inst Inc * Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy.
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
WO2012027716A1 (en) 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
KR20130137624A (en) * 2010-09-03 2013-12-17 브리스톨-마이어스 스큅 컴퍼니 Drug formulations using water soluble antioxidants
JP2014505658A (en) 2010-11-05 2014-03-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド How to treat cancer
WO2012068468A1 (en) 2010-11-19 2012-05-24 Glaxosmithkline Llc Method of treatment with braf inhibitor
EP2640860A4 (en) 2010-11-19 2014-06-04 Univ California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
US9295669B2 (en) * 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
TWI505828B (en) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 Novel pharmaceutical composition
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
KR20220165811A (en) * 2012-08-17 2022-12-15 에프. 호프만-라 로슈 아게 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
CN104994879A (en) 2013-02-22 2015-10-21 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance

Also Published As

Publication number Publication date
UA114923C2 (en) 2017-08-28
AU2013304021B2 (en) 2016-09-15
KR20220165811A (en) 2022-12-15
EA033573B1 (en) 2019-11-06
MX2015002031A (en) 2015-06-05
ES2743427T3 (en) 2020-02-19
MX367970B (en) 2019-09-11
AU2013304021A1 (en) 2015-02-12
HRP20191533T1 (en) 2019-11-29
CN104640545A (en) 2015-05-20
CO7180225A2 (en) 2015-02-09
NZ744862A (en) 2019-06-28
US11783366B2 (en) 2023-10-10
EP2884979A1 (en) 2015-06-24
HK1206605A1 (en) 2016-01-15
SI2884979T1 (en) 2019-10-30
US20240046303A1 (en) 2024-02-08
EP2884979B1 (en) 2019-06-26
IL237065B (en) 2020-07-30
EA201590262A1 (en) 2015-06-30
IL237065A0 (en) 2015-03-31
DK2884979T3 (en) 2019-09-02
KR20190057421A (en) 2019-05-28
JP2015531763A (en) 2015-11-05
HUE044789T2 (en) 2019-11-28
JP6335169B2 (en) 2018-05-30
BR112015003418A2 (en) 2017-07-04
CA2928396A1 (en) 2014-02-20
CN110251512A (en) 2019-09-20
CA2879252C (en) 2017-10-10
PH12015500186A1 (en) 2015-04-06
WO2014027056A1 (en) 2014-02-20
JP2017160214A (en) 2017-09-14
US11087354B2 (en) 2021-08-10
PL2884979T3 (en) 2019-11-29
KR20210108502A (en) 2021-09-02
SG10201708494QA (en) 2017-11-29
MY180613A (en) 2020-12-03
KR20170044759A (en) 2017-04-25
RS59113B1 (en) 2019-09-30
LT2884979T (en) 2019-09-10
SG11201500582UA (en) 2015-04-29
KR20150038068A (en) 2015-04-08
PT2884979T (en) 2019-09-04
US20140093568A1 (en) 2014-04-03
ZA201500348B (en) 2019-07-31
CL2015000345A1 (en) 2015-05-22
CA2879252A1 (en) 2014-02-20
PE20151156A1 (en) 2015-08-19
US20220172244A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
HK1206605A1 (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafinib cobimetinib
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
HK1211475A1 (en) Combination therapy
HK1205298A1 (en) Hardware and software association and authentication
HK1203493A1 (en) Substituted azabicycles and use thereof
EP2884984A4 (en) Therapeutic compositions and methods
EP2806918A4 (en) Methods and devices for autoflush syringes
EP2867209A4 (en) Compounds and therapeutic uses thereof
EP2914254A4 (en) Combination therapies
EP2875014A4 (en) Anti-mucus drugs and uses therefor
GB201216649D0 (en) Agents and methods
GB201217439D0 (en) Combination therapy
HK1203198A1 (en) Substituted phenylimidazopyrazoles and use thereof
HK1210426A1 (en) Combination therapy
EP2895186A4 (en) Therapeutic compositions and related methods
EP2817004A4 (en) Bouvardin derivatives and therapeutic uses thereof
HK1207154A1 (en) C1q-adiponectin complex and use thereof c1q-
GB201222541D0 (en) Kiddibidet and pottibidet
GB201214493D0 (en) Therapies
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202945D0 (en) Novel cancer therapies and methods
GB201202021D0 (en) Co-sleeper and breastfeeder
EP2922862A4 (en) Complex-formation-modulating agents and uses therefor
GB201418806D0 (en) Generating and partitioning polynomials
GB201211543D0 (en) Combination therapy